VEGFA and dementia: Similarly, a pharmacovigilance study analyzing over 18 million spontaneous safety reports found a statistical signal linking intravitreal ranibizumab, an anti-VEGF therapy, to increased reports of dementia and Parkinson-like syndromes, suggesting a possible risk of cognitive and motor decline following chronic anti-VEGF exposure [49].